Blood Disorder Program: Prevention, Surveillance, and Research

 

To work with State health agencies and other public, private, and nonprofit organizations in planning, development, implementation, coordination, or evaluation of programs or other activities related to improved blood disorders. To provide a national, State or local focus for the prevention of conditions in persons with blood disorders; to employ epidemiological methods to set priorities, build capacity and direct health promotion interventions for persons with blood disorders. To expand public health training opportunities through fellowships to introduce geneticists, epidemiologists, and clinicians to public health practice through education, training and career-enhancing experiences.

Active 93.080 Centers For Disease Control and Prevention, Department of Health and Human Services B - Project Grants Not applicable. Public Health Service Act Sections 301, 301(a), 311, and 317C (42 U.S.C. Sections 241, 241(a), 237b-4, 243, 247-4, and 247b-4, as amended Not applicable. Not applicable. Applicants should document the need for assistance, state the objectives of the project, outline the method of operation, describe evaluation procedures, and provide a budget with justification for funds requested. Preapplication coordination is not applicable. This program is excluded from coverage under 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any.Cooperative agreement awards and grants, competitive and single eligibility, are determined by an internal objective committee review process at CDC, including peer reviews for research activities. Awards will be based on evaluation criteria set forth in the respective Notice of Funding Opportunity, the availability of funds, and such other significant factors as deemed necessary and appropriate by CDC. Contact the headquarters or regional location, as appropriate for application deadlines From 90 to 120 days. Not applicable. Project period of performance is 1 to 5 years. After initial awards, and subject to availability of funds, projects may be continued non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government. Applications will be evaluated on the review criteria described in the Notice of Funding Opportunity Announcements (NOFOs). In general, the review and selection process of complete and responsive applications to the NOFO consists of determination of the scientific and technical merit by objective or peer review, availability of funds, and relevance of program priorities and the priorities of CDC. Funds may be used to strengthen, to expand, to build upon or to enhance surveillance, health promotion, education and training, prevention/intervention activities that contribute to the mission and activities of the Division of Blood Disorders. Funds may be used to improve and strengthen State and local public health infrastructure by providing technical assistance to other appropriate health agencies, organizations, special groups or coalitions. Funds may be used to support capacity building, program planning, development, implementation, evaluation, and surveillance for blood disorders outcomes, including related health promotion, education and training, and prevention/intervention. Funds may also be used to coordinate the dissemination of prevention information to the general public, target populations and among state and local agencies and public and private sector organizations in the United States. Performance Reports: Annual Federal Financial Reports (FFR) and performance/progress reports are required. Final FFRs and performance reports are required. Other reporting may be required and will be outlined in the NOFO or the Notice of Award. Not applicable. In accordance with 2 CFR ?200, as codified in 45 CFR ?75, there is a 3-year record retention requirement; records shall be retained beyond the 3-year period if final audit has not been done or findings resolved. Property records must be retained in accordance with HHS Grants Policy Statement requirements. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient. Notice of Award None/Not specified. Shelia Jones
4770 Buford Highway
Mailstop E87
Atlanta, GA 30341 US
sjones3@cdc.gov
Phone: 4044983995 http://www.cdc.gov 75-0958-1-1-550 (Cooperative Agreements) FY 22$10,366,723.00; FY 23 est $11,282,178.00; FY 24 FY 21$11,282,178.00; FY 20$8,466,345.00; - Financial Assistance is dependent upon funding availability. Award amounts range from $57,000 to $4,300,000. Regulations governing this program are published under 45 CFR Part 75. Fiscal Year 2017 Evaluation of Health Promotion and Prevention Programs for Blood Disorders; Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies; Public Health Surveillance for the Prevention of Complications of Bleeding & Clotting Disorders
Fiscal Year 2019 DD19-1903, Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies
Fiscal Year 2020 DD20-2002, Evaluation of Health Promotion and Prevention Programs for Blood Disorders; DD 20-2004 American Thrombosis and Hemostasis Network